Updated Comparison of 7/8 HLA Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Umbilical Cord Blood Transplantation as Alternative Donors in Adults with Acute Leukemia

IF 4.3 Q1 Medicine
Kotaro Miyao , Seitaro Terakura , Fumihiko Kimura , Takaaki Konuma , Koichi Miyamura , Masamitsu Yanada , Shinichi Kako , Satoko Morhishima , Naoyuki Uchida , Takashi Toya , Yukiyasu Ozawa , Takahiro Fukuda , Masatsugu Tanaka , Masashi Sawa , Satoru Takada , Shuro Yoshida , Takafumi Kimura , Tatsuo Ichinohe , Yoshiko Atsuta , Junya Kanda
{"title":"Updated Comparison of 7/8 HLA Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Umbilical Cord Blood Transplantation as Alternative Donors in Adults with Acute Leukemia","authors":"Kotaro Miyao ,&nbsp;Seitaro Terakura ,&nbsp;Fumihiko Kimura ,&nbsp;Takaaki Konuma ,&nbsp;Koichi Miyamura ,&nbsp;Masamitsu Yanada ,&nbsp;Shinichi Kako ,&nbsp;Satoko Morhishima ,&nbsp;Naoyuki Uchida ,&nbsp;Takashi Toya ,&nbsp;Yukiyasu Ozawa ,&nbsp;Takahiro Fukuda ,&nbsp;Masatsugu Tanaka ,&nbsp;Masashi Sawa ,&nbsp;Satoru Takada ,&nbsp;Shuro Yoshida ,&nbsp;Takafumi Kimura ,&nbsp;Tatsuo Ichinohe ,&nbsp;Yoshiko Atsuta ,&nbsp;Junya Kanda","doi":"10.1016/j.bbmt.2020.08.001","DOIUrl":null,"url":null,"abstract":"<div><p>The outcomes of 7/8 allele-matched unrelated bone marrow transplantation (7/8 UBMT) and umbilical cord blood transplantation (UCBT) have been improving. We retrospectively analyzed adults with acute leukemia who underwent their first 7/8 UBMT or UCBT in Japan. Between January 2008 and December 2017, a total of 4150 patients were recorded, including 488 who underwent 7/8 UBMT and 3662 who underwent UCBT. Only 32 patients with 7/8 UBMT had graft-versus-host-disease (GVHD) high-risk HLA mismatched pairs. Overall survival at 3 years was 54% for 7/8 the UBMT group and 46% for the UCBT group, a nonsignificant difference in multivariate analysis (hazard ratio [HR], 1.01; 95% confidence interval [CI], .88 to 1.17; <em>P</em> = .89). The 7/8 UBMT and UCBT groups showed a similar nonrelapse mortality rate (HR, 1.16; 95% CI, .96 to 1.45; <em>P</em> = .16) and relapse rate (HR, .85; 95% CI, .71 to 1.02; <em>P</em> = .08). However, the UCBT group had a lower risk of grade II-IV acute GVHD (HR, .76; 95% CI, .65 to .88; <em>P</em> &lt; .001) and chronic GVHD (HR, .77; 95% CI, .66- .91; <em>P</em> = .002) compared with the 7/8 UBMT group. In stratified analyses combining disease risk with conditioning intensity, 7/8 UBMT showed superior overall survival to UCBT in standard risk and myeloablative conditioning (HR, .72; 95% CI, .56 to .93; <em>P</em> = .014). Both 7/8 UBMT and UCBT are appropriate alternative donor procedures. The stem cell source can be selected on the basis of disease risk, patient tolerability, or concerns regarding GVHD.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 11","pages":"Pages 2105-2114"},"PeriodicalIF":4.3000,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.08.001","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biology of Blood and Marrow Transplantation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1083879120304699","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 13

Abstract

The outcomes of 7/8 allele-matched unrelated bone marrow transplantation (7/8 UBMT) and umbilical cord blood transplantation (UCBT) have been improving. We retrospectively analyzed adults with acute leukemia who underwent their first 7/8 UBMT or UCBT in Japan. Between January 2008 and December 2017, a total of 4150 patients were recorded, including 488 who underwent 7/8 UBMT and 3662 who underwent UCBT. Only 32 patients with 7/8 UBMT had graft-versus-host-disease (GVHD) high-risk HLA mismatched pairs. Overall survival at 3 years was 54% for 7/8 the UBMT group and 46% for the UCBT group, a nonsignificant difference in multivariate analysis (hazard ratio [HR], 1.01; 95% confidence interval [CI], .88 to 1.17; P = .89). The 7/8 UBMT and UCBT groups showed a similar nonrelapse mortality rate (HR, 1.16; 95% CI, .96 to 1.45; P = .16) and relapse rate (HR, .85; 95% CI, .71 to 1.02; P = .08). However, the UCBT group had a lower risk of grade II-IV acute GVHD (HR, .76; 95% CI, .65 to .88; P < .001) and chronic GVHD (HR, .77; 95% CI, .66- .91; P = .002) compared with the 7/8 UBMT group. In stratified analyses combining disease risk with conditioning intensity, 7/8 UBMT showed superior overall survival to UCBT in standard risk and myeloablative conditioning (HR, .72; 95% CI, .56 to .93; P = .014). Both 7/8 UBMT and UCBT are appropriate alternative donor procedures. The stem cell source can be selected on the basis of disease risk, patient tolerability, or concerns regarding GVHD.

7/8 HLA等位基因匹配非相关骨髓移植和单单位脐带血移植作为急性白血病成人替代供体的最新比较
7/8等位基因匹配非相关骨髓移植(7/8 UBMT)和脐带血移植(UCBT)的预后一直在改善。我们回顾性分析了在日本首次接受7/8 UBMT或UCBT的急性白血病成人患者。在2008年1月至2017年12月期间,共记录了4150例患者,其中488例接受了7/8 UBMT, 3662例接受了UCBT。只有32例7/8 UBMT患者存在移植物抗宿主病(GVHD)高危HLA错配对。7/8 UBMT组3年总生存率为54%,UCBT组为46%,多因素分析差异无统计学意义(风险比[HR], 1.01;95%置信区间[CI], 0.88 ~ 1.17;p = .89)。7/8 UBMT组和UCBT组的非复发死亡率相似(HR, 1.16;95% CI, 0.96 ~ 1.45;P = 0.16)和复发率(HR, 0.85;95% CI, 0.71 ~ 1.02;p = .08)。然而,UCBT组发生II-IV级急性GVHD的风险较低(HR, 0.76;95% CI, 0.65 ~ 0.88;P & lt;.001)和慢性GVHD (HR, .77;95% ci, 0.66 - 0.91;P = .002)与7/8 UBMT组比较。在结合疾病风险和调节强度的分层分析中,在标准风险和清髓调节中,7/8 UBMT的总生存率优于UCBT (HR, 0.72;95% CI, 0.56 ~ 0.93;p = .014)。7/8 UBMT和UCBT都是合适的替代供体程序。干细胞来源可以根据疾病风险、患者耐受性或对GVHD的关注来选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.60
自引率
0.00%
发文量
1061
审稿时长
3-6 weeks
期刊介绍: Biology of Blood and Marrow Transplantation publishes original research reports, reviews, editorials, commentaries, letters to the editor, and hypotheses and is the official publication of the American Society for Transplantation and Cellular Therapy. The journal focuses on current technology and knowledge in the interdisciplinary field of hematopoetic stem cell transplantation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信